Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis.

Manka P, Bechmann L, Best J, Sydor S, Claridge LC, Coombes JD, Canbay A, Moeller L, Gerken G, Wedemeyer H, Syn WK.

Dig Dis Sci. 2019 Jun 3. doi: 10.1007/s10620-019-05687-3. [Epub ahead of print]

PMID:
31155687
2.

Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities.

Manka P, Zeller A, Syn WK.

Drugs. 2019 Jun;79(9):903-927. doi: 10.1007/s40265-019-01126-9.

PMID:
31119644
3.

Non-nutritive sweeteners and their association with the metabolic syndrome and non-alcoholic fatty liver disease: a review of the literature.

Green CH, Syn WK.

Eur J Nutr. 2019 May 22. doi: 10.1007/s00394-019-01996-5. [Epub ahead of print] Review.

PMID:
31119399
4.

The motor protein Myo1c regulates transforming growth factor-β-signaling and fibrosis in podocytes.

Arif E, Solanki AK, Srivastava P, Rahman B, Tash BR, Holzman LB, Janech MG, Martin R, Knölker HJ, Fitzgibbon WR, Deng P, Budisavljevic MN, Syn WK, Wang C, Lipschutz JH, Kwon SH, Nihalani D.

Kidney Int. 2019 Jul;96(1):139-158. doi: 10.1016/j.kint.2019.02.014. Epub 2019 Mar 4.

PMID:
31097328
5.

Current treatment options for nonalcoholic fatty liver disease.

Shetty A, Syn WK.

Curr Opin Gastroenterol. 2019 May;35(3):168-176. doi: 10.1097/MOG.0000000000000528.

PMID:
30844893
7.

Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth.

Dismuke-Greer CE, Syn WK.

Dig Dis Sci. 2019 Mar;64(3):606-608. doi: 10.1007/s10620-018-5426-4. No abstract available.

PMID:
30560337
8.

Role of Metabolism in Hepatic Stellate Cell Activation and Fibrogenesis.

Hou W, Syn WK.

Front Cell Dev Biol. 2018 Nov 12;6:150. doi: 10.3389/fcell.2018.00150. eCollection 2018.

9.

Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Glass O, Henao R, Patel K, Guy CD, Gruss HJ, Syn WK, Moylan CA, Streilein R, Hall R, Mae Diehl A, Abdelmalek MF.

Hepatol Commun. 2018 Sep 21;2(11):1344-1355. doi: 10.1002/hep4.1237. eCollection 2018 Nov.

10.

Atorvastatin provides a new lipidome improving early regeneration after partial hepatectomy in osteopontin deficient mice.

Nuñez-Garcia M, Gomez-Santos B, Saenz de Urturi D, Mestre D, Gonzalez-Romero F, Buque X, Gutiérrez-de Juan V, Martinez-Chantar ML, Syn WK, Fresnedo O, Aspichueta P.

Sci Rep. 2018 Oct 2;8(1):14626. doi: 10.1038/s41598-018-32919-9.

11.

Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease.

Shetty A, Hsu JW, Manka PP, Syn WK.

Dig Dis Sci. 2018 Dec;63(12):3187-3206. doi: 10.1007/s10620-018-5242-x. Epub 2018 Aug 18. Review.

PMID:
30121811
12.

Profile of drug resistance mutations in nucleos(t)ide analogue-experienced chronic hepatitis B patients in Tianjin, China.

Hou W, Trieu C, Du Y, Wang C, Syn WK.

Int J Antimicrob Agents. 2018 Nov;52(5):735-736. doi: 10.1016/j.ijantimicag.2018.07.024. Epub 2018 Aug 3. No abstract available.

PMID:
30081141
13.

Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection.

Naggie S, Swiderska-Syn M, Choi S, Lusk S, Lan A, Ferrari G, Syn WK, Guy CD, Diehl AM.

Open Forum Infect Dis. 2018 Jun 11;5(7):ofy138. doi: 10.1093/ofid/ofy138. eCollection 2018 Jul.

14.

Beyond the liver in patients with non-alcoholic fatty liver disease (NAFLD)-cause for concern?

Armstrong MJ, Haydon G, Syn WK.

Hepatobiliary Surg Nutr. 2018 Apr;7(2):138-142. doi: 10.21037/hbsn.2018.01.09. No abstract available.

15.

Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent.

De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM, Foster GR, Syn WK, Alazawi W.

Frontline Gastroenterol. 2018 Apr;9(2):115-121. doi: 10.1136/flgastro-2017-100865. Epub 2017 Nov 16.

16.

Iron Enhances Hepatic Fibrogenesis and Activates Transforming Growth Factor-β Signaling in Murine Hepatic Stellate Cells.

Mehta KJ, Coombes JD, Briones-Orta M, Manka PP, Williams R, Patel VB, Syn WK.

Am J Med Sci. 2018 Feb;355(2):183-190. doi: 10.1016/j.amjms.2017.08.012. Epub 2017 Aug 23.

PMID:
29406047
17.

Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease.

Alazawi W, Bernabe E, Tai D, Janicki T, Kemos P, Samsuddin S, Syn WK, Gillam D, Turner W.

PLoS One. 2017 Dec 8;12(12):e0185902. doi: 10.1371/journal.pone.0185902. eCollection 2017.

18.

Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease.

Shetty A, Cho W, Alazawi W, Syn WK.

Am J Med Sci. 2017 Aug;354(2):172-181. doi: 10.1016/j.amjms.2017.03.014. Epub 2017 Mar 14. Review.

PMID:
28864376
19.

Prediction of transcription factor bindings sites affected by SNPs located at the osteopontin promoter.

Briones-Orta MA, Avendaño-Vázquez SE, Ivette Aparicio-Bautista D, Coombes JD, Weber GF, Syn WK.

Data Brief. 2017 Aug 2;14:538-542. doi: 10.1016/j.dib.2017.07.057. eCollection 2017 Oct.

20.

Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver.

Nuñez-Garcia M, Gomez-Santos B, Buqué X, García-Rodriguez JL, Romero MR, Marin JJG, Arteta B, García-Monzón C, Castaño L, Syn WK, Fresnedo O, Aspichueta P.

J Lipid Res. 2017 Sep;58(9):1903-1915. doi: 10.1194/jlr.M078980. Epub 2017 Jul 28.

Supplemental Content

Loading ...
Support Center